- Implantable cardiac rhythm management (CRM) refers to the use of implanted medical devices to monitor, regulate, and correct abnormal heart rhythms (arrhythmias). These devices help manage conditions such as bradycardia (slow heart rate), tachycardia (fast heart rate), and heart failure
- The market growth is largely fueled by the increasing prevalence of cardiovascular diseases, such as arrhythmias, heart failure, and sudden cardiac arrest, driven by factors including the aging global population and rising lifestyle-related risk factors. This has led to a growing demand for advanced diagnostic and therapeutic solutions in cardiac care
- North America dominates the implantable cardiac rhythm management market with the largest revenue share of 42.23% in 2024, characterized by a highly developed healthcare infrastructure, high awareness and adoption of advanced medical technologies, and significant investments in research and development by key industry players
- Asia-Pacific is expected to be the fastest growing region in the Implantable cardiac rhythm management market during the forecast period with a CAGR of 7.4% from 2025 to 2032, due to increasing urbanization, rising disposable incomes, and the growing incidence of cardiovascular diseases, alongside improving healthcare infrastructure and increasing awareness in countries such as China and India
- Defibrillators segment dominates the implantable cardiac rhythm management market with a market share of 45.9%, driven by the high demand for life-saving devices such as Implantable Cardioverter Defibrillators (ICDs) and external defibrillators for treating cardiac arrhythmias and sudden cardiac arrest
